ClinicalTrials.gg
DrugBiological

Epcoritamab clinical trials

Also written GEN3013 and Epkinly.

studies test it
57
open now
40
in phase 3
5
first study started
2018

How each study uses epcoritamab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the epcoritamab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
19 May 2023 · EPKINLY · BLA 761324 (FDA, Drugs@FDA)
European Union
22 Sept 2023 · Tepkinly · EMEA/H/C/005985 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Epcoritamab
55
DuoBody-CD3xCD20
21
Epcoritamab-bysp
13
Anti-CD20/CD3 Bispecific Antibody GEN3013
12
Tepkinly
10

Brand

Epkinly
23

Development codes

GEN3013
24

Studies by the year they started

56 studies that test it; most in 2025 (17); 1 more planned to start later

Studies that test epcoritamab, by start year
YearStudies
20181
20203
20211
20225
20235
202410
202517
202614

By phase

A phase 1/2 study counts in both.

Phase 1
14
Phase 2
45
Phase 3
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 13 · Other 44

Genmab (13) · City of Hope Medical Center (4) · The Lymphoma Academic Research Organisation (3) · National Heart, Lung, and Blood Institute (NHLBI) (2) · M.D. Anderson Cancer Center (2) · Stichting Hemato-Oncologie voor Volwassenen Nederland (2) · Reid Merryman, MD (2) · Memorial Sloan Kettering Cancer Center (2)

Often tested with

Tested in the same studies.

Lenalidomide (9) · Rituximab (7) · Oxaliplatin (3) · Gemcitabine (3) · Ibrutinib (3) · Venetoclax (3) · Pirtobrutinib (2) · Loncastuximab tesirine (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 16

Studies that test epcoritamab.

Studies

Open first, then newest update. How each study uses epcoritamab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 57

See all 57 studies that test epcoritamab →

Given beside what is tested · 5 — epcoritamab is usual care or a partner of the new treatment

Codes

What other systems call epcoritamab · ClinicalTrials.gg INT002168

  • MeSH (NLM) C000731938epcoritamabOne source NLM
  • UNII (FDA) D6OMY2L0WAEPCORITAMABConfirmed FDA, NLM, Wikidata
  • Wikidata Q119025940epcoritamabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C163022EpcoritamabOne source FDA
  • DrugBank DB16672One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.